a decreasing trendP = 0.072
Interestingly, the IOP between the control group and control+VitK1 group also demonstrated a decreasing trend (14.49 ± 1.05 vs 13.49 ± 0.86; P = 0.072) ( Fig. 2 A).
Interestingly, the IOP between the control group and control+VitK1 group also demonstrated a decreasing trend (14.49 ± 1.05 vs 13.49 ± 0.86; P = 0.072) ( Fig. 2 A).
2 Abundant experimental and clinical studies have been carried out to pursue and develop effective neuroprotection therapeutics in glaucoma, which is highly significant and valuable in the field of glaucoma treatment. 3 Hence, innovative approaches of neuroprotection are necessary to develop more potential options for glaucoma treatment. 4 Oxidative stress is presumed to play a crucial role in the neurodegenerative process of glaucoma. 5 Apart from its neurodegenerative effect on the optic nerve, oxidative stress has also been shown to damage another major target tissue of glaucoma: trabecular meshwork (TM).